The Argument Against a Biosimilar Switch Policy for Infliximab in Patients with Inflammatory Bowel Disease Living in Alberta
暂无分享,去创建一个
[1] T. Caulfield,et al. The Law and Ethics of Switching from Biologic to Biosimilar in Canada , 2020, Journal of the Canadian Association of Gastroenterology.
[2] P. Moayyedi,et al. Joint Canadian Association of Gastroenterology and Crohn’s Colitis Canada Position Statement on Biosimilars for the Treatment of Inflammatory Bowel Disease , 2019, Journal of the Canadian Association of Gastroenterology.
[3] H. El‐Serag,et al. Recommendations for Successful Transition of Adolescents With Inflammatory Bowel Diseases to Adult Care. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[4] Siddharth Singh,et al. Management of Inflammatory Bowel Diseases in Special Populations: Obese, Old or Obstetric. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[5] S. Ghaly,et al. Switching Australian patients with moderate to severe inflammatory bowel disease from originator infliximab to biosimilar Inflectra: Interim results from a multicenter parallel cohort study , 2019 .
[6] S. Vermeire,et al. Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center. , 2019, Inflammatory bowel diseases.
[7] D. Mitsikostas,et al. Nocebo in Biosimilars and Generics in Neurology: A Systematic Review , 2019, Front. Pharmacol..
[8] S. Coward. Forecasting the Future: A Trek through the Changing Landscape of Inflammatory Bowel Disease , 2019 .
[9] M. Skup,et al. Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review , 2019, Advances in Therapy.
[10] S. Ng,et al. Trends in hospitalisation rates for inflammatory bowel disease in western versus newly industrialised countries: a population-based study of countries in the Organisation for Economic Co-operation and Development. , 2019, The lancet. Gastroenterology & hepatology.
[11] G. Kaplan,et al. Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data. , 2019, Gastroenterology.
[12] G. Veres,et al. Use of Biosimilars in Pediatric Inflammatory Bowel Disease: An Updated Position Statement of the Pediatric IBD Porto Group of ESPGHAN , 2019, Journal of pediatric gastroenterology and nutrition.
[13] G. Kaplan,et al. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization , 2018, Journal of the Canadian Association of Gastroenterology.
[14] G. Kaplan,et al. The Impact of Inflammatory Bowel Disease in Canada 2018: A Scientific Report from the Canadian Gastro-Intestinal Epidemiology Consortium to Crohn’s and Colitis Canada , 2018, Journal of the Canadian Association of Gastroenterology.
[15] G. Kaplan,et al. The Impact of Inflammatory Bowel Disease in Canada 2018: IBD in Seniors , 2018, Journal of the Canadian Association of Gastroenterology.
[16] G. Kaplan,et al. The Impact of Inflammatory Bowel Disease in Canada 2018: Epidemiology , 2018, Journal of the Canadian Association of Gastroenterology.
[17] G. Kaplan,et al. The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD , 2018, Journal of the Canadian Association of Gastroenterology.
[18] S. Vermeire,et al. Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease , 2019, Therapeutic drug monitoring.
[19] M. Skup,et al. Short-term costs associated with non-medical switching in autoimmune conditions. , 2019, Clinical and experimental rheumatology.
[20] L. Peyrin-Biroulet,et al. Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review. , 2019, Current medicinal chemistry.
[21] M. Calleja,et al. Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease , 2018, World journal of gastroenterology.
[22] C. Lees,et al. Implementation of CT-P13 via a Managed Switch Programme in Crohn’s Disease: 12-Month Real-World Outcomes , 2018, Digestive Diseases and Sciences.
[23] G. Kaplan,et al. Depression increases the risk of inflammatory bowel disease, which may be mitigated by the use of antidepressants in the treatment of depression , 2018, Gut.
[24] Gregory A. Heindel,et al. The Biosimilar Nocebo Effect? A Systematic Review of Double-Blinded Versus Open-Label Studies , 2018, Journal of managed care & specialty pharmacy.
[25] L. Peyrin-Biroulet,et al. The nocebo effect: a clinical challenge in the era of biosimilars , 2018, Expert review of clinical immunology.
[26] M. Regueiro,et al. ACG Clinical Guideline: Management of Crohn’s Disease in Adults , 2018, The American Journal of Gastroenterology.
[27] Sandra C. Kim,et al. Assuring Quality for Non-hospital–based Biologic Infusions in Pediatric Inflammatory Bowel Disease: A Clinical Report From the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition , 2018, Journal of pediatric gastroenterology and nutrition.
[28] Y. Choe,et al. Long-term Outcomes After Switching to CT-P13 in Pediatric-Onset Inflammatory Bowel Disease: A Single-Center Prospective Observational Study. , 2018, Inflammatory bowel diseases.
[29] S. Vermeire,et al. Immunogenicity of biologics in inflammatory bowel disease , 2018, Therapeutic advances in gastroenterology.
[30] Subrata Ghosh,et al. Surgical Rates for Crohn’s Disease are Decreasing: A Population-Based Time Trend Analysis and Validation Study , 2017, The American Journal of Gastroenterology.
[31] D. Rubin,et al. Effects of non-medical switching on outcomes among patients prescribed tumor necrosis factor inhibitors , 2017, Current medical research and opinion.
[32] K. Phillips,et al. SAT0172 Economic outcomes, treatment patterns, and adverse events and reactions for patients prescribed infliximab or ct-p13 in the turkish population , 2017 .
[33] L. Downey,et al. Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme , 2017, Journal of Crohn's & colitis.
[34] Inge Christoffer Olsen,et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial , 2017, The Lancet.
[35] D. Roccatello,et al. Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review , 2017, BioDrugs.
[36] C. Piech,et al. Impact of non-medical switching on clinical and economic outcomes, resource utilization and medication-taking behavior: a systematic literature review , 2016, Current medical research and opinion.
[37] A. Bitton,et al. The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. , 2016, Gastroenterology.
[38] G. Kaplan,et al. Postoperative Mortality Among Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis of Population-Based Studies. , 2015, Gastroenterology.
[39] J. Xu,et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. , 2014, Gastroenterology.
[40] G. Kaplan,et al. Postoperative complications and mortality following colectomy for ulcerative colitis. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[41] S. Ben-Horin,et al. Review article: loss of response to anti‐TNF treatments in Crohn’s disease , 2011, Alimentary pharmacology & therapeutics.
[42] G. Guyatt,et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.
[43] S. Hanauer,et al. Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab , 2007, Annals of Internal Medicine.
[44] J. Mawdsley,et al. RECENT ADVANCES IN BASIC SCIENCE PSYCHOLOGICAL STRESS IN IBD: NEW INSIGHTS INTO PATHOGENIC AND THERAPEUTIC IMPLICATIONS , 2005 .